Articles On Phylogica (ASX:PYC)
| Title | Source | Codes | Date |
|---|---|---|---|
|
Phylogica achieves milestone in drug study aimed at treating childhood blindness
Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from it... |
SmallCaps | PYC | 5 years ago |
|
Rise & Shine: What you need to know before the ASX opens
On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on... |
Stockhead | PYC | 5 years ago |
|
Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease
A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitiv... |
SmallCaps | PYC | 5 years ago |
|
10 at 10: These ASX stocks are being rescued this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | PYC | 5 years ago |
|
Three ASX Players Catering to Health Sector- CLI, PYC, BDA
Australia is known to have one of the world’s best health system, which provides quality, safe and reasonable healthcare to individuals. This is the reason which places Australia among the countries with the longest life expectancies in the... |
Kalkine Media | PYC | 5 years ago |
|
Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding eye diseases
Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for blinding genetic eye diseases. The study d... |
SmallCaps | PYC | 5 years ago |
|
Top 10 at 10: These stocks are dodging the fallen today
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | PYC | 5 years ago |
|
Phylogica obtains successful time-course study results for flagship CPP platform
Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed. The most recent animal model results als... |
SmallCaps | PYC | 5 years ago |
|
Phylogica just scored a key win for its patented eye treatment technology
Medical tech company Phylogica (ASX: PYC) has cleared an important hurdle in the development of its patented drug delivery platform. The company’s operating focus is on improving the complex procedures used to transmit drugs to the eye. Ear... |
Stockhead | PYC | 5 years ago |